NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis $1.18 0.00 (0.00%) Closing price 04:10 PM EasternExtended Trading$1.16 -0.02 (-1.69%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Theriva Biologics Stock (NYSEAMERICAN:TOVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theriva Biologics alerts:Sign Up Key Stats Today's Range$1.07▼$1.1850-Day Range$1.10▼$1.7252-Week Range$1.03▼$12.28Volume10,875 shsAverage Volume994,946 shsMarket Capitalization$3.28 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewTheriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.Read More… Remove Ads Theriva Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreTOVX MarketRank™: Theriva Biologics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTheriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTheriva Biologics has received no research coverage in the past 90 days.Read more about Theriva Biologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheriva Biologics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.55% of the float of Theriva Biologics has been sold short.Short Interest Ratio / Days to CoverTheriva Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theriva Biologics has recently decreased by 16.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheriva Biologics does not currently pay a dividend.Dividend GrowthTheriva Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.55% of the float of Theriva Biologics has been sold short.Short Interest Ratio / Days to CoverTheriva Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theriva Biologics has recently decreased by 16.92%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.52 News SentimentTheriva Biologics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Theriva Biologics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Theriva Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Theriva Biologics is held by insiders.Percentage Held by InstitutionsOnly 6.17% of the stock of Theriva Biologics is held by institutions.Read more about Theriva Biologics' insider trading history. Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address TOVX Stock News HeadlinesTheriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025April 2 at 11:39 AM | nasdaq.comTheriva Biologics says IDMC considers VCN-01 to be well toleratedApril 2 at 11:39 AM | markets.businessinsider.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 3, 2025 | Porter & Company (Ad)Theriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New OrleansMarch 21, 2025 | nasdaq.comTheriva™ Biologics to Present at the 2025 NeauxCancer ConferenceMarch 19, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)March 12, 2025 | markets.businessinsider.comTheriva Biologics Reports 2024 Financial Results and ProgressMarch 7, 2025 | tipranks.comTheriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial ResultsMarch 6, 2025 | globenewswire.comSee More Headlines TOVX Stock Analysis - Frequently Asked Questions How have TOVX shares performed this year? Theriva Biologics' stock was trading at $1.65 at the start of the year. Since then, TOVX shares have decreased by 28.5% and is now trading at $1.18. View the best growth stocks for 2025 here. How were Theriva Biologics' earnings last quarter? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($6.81) EPS for the quarter, missing analysts' consensus estimates of ($6.25) by $0.56. When did Theriva Biologics' stock split? Shares of Theriva Biologics reverse split on Monday, August 26th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theriva Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Daré Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX). Company Calendar Last Earnings11/12/2024Today4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:TOVX CIK894158 Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+417.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($33.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.12% Return on Assets-48.54% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$54.22 per share Price / Book0.02Miscellaneous Outstanding Shares2,780,000Free Float2,697,000Market Cap$3.22 million OptionableNot Optionable Beta1.22 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NYSEAMERICAN:TOVX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.